Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis

Published:2022-05-30 Issue: Volume: Page:
ISSN:1941-6628
Container-title:Journal of Gastrointestinal Cancer
language:en
Short-container-title:J Gastrointest Canc

Author:

Mishra Gauri^ORCID,Majeed Ammar,Dev Anouk,Eslick Guy D.,Pinato David J.,Izumoto Hirofumi,Hiraoka Atsushi,Huo Teh-Ia,Liu Po-Hong,Johnson Philip J.,Roberts Stuart K.

Funder

Faculty of Medicine, Nursing and Health Sciences, Monash University

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s12029-022-00832-0.pdf

Reference78 articles.

1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alemayohu MA, Allen C, et al. Global burden of disease cancer collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2018;68(6):394–424.

3. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.